Ligand Pharmaceuticals/LGND

$89.20

19.86%
-
1D1W1MYTD1YMAX

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. The Company is focused on acquiring or funding programs and technologies that pharmaceutical companies use to discover and develop medicines. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Its Pelican Expression technology is a scalable platform for recombinant protein production, and is especially suited for complex, large-scale protein production. Its products include Kyprolis, Teriparatide, Evomela, Rylaze, Nexterone, Pneumosil, Vaxneuvance, and others. Kyprolis is formulated with its Captisol technology. Teriparatide Injection is a drug indicated for use including the treatment of osteoporosis in certain patients at high risk for fracture. Evomela is a Captisol-enabled melphalan IV formulation. It also owns berdazimer gel and all the assets related to the NITRICIL technology platform, and rights to Sitavig program.

Ticker

LGND

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Todd Davis

Employees

76

Headquarters

San diego, United States

LGND Metrics

BasicAdvanced
$1.3B
Market cap
88.93
P/E ratio
$0.84
EPS
1.04
Beta
-
Dividend rate

What the Analysts think about LGND

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 5 analysts.
28.7% upside
High $144.00
Low $90.00
$89.20
Current price
$114.80
Average price target

LGND Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-31.09% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$32.8M
24.71%
Net income
$-10.2M
-563.64%
Profit margin
-31.09%
-471.89%

LGND Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 67.21%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$2.28
$1.42
$1.02
-
-
Expected
$0.89
$0.64
$0.61
$0.66
$0.97
Surprise
155.03%
121.96%
67.21%
-
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Ligand Pharmaceuticals stock

Buy or sell Ligand Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing